We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Physiomics Plc | LSE:PYC | London | Ordinary Share | GB00BDR6W943 | ORD 0.4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.05 | -3.70% | 1.30 | 1.20 | 1.40 | 1.35 | 1.30 | 1.35 | 1,369,680 | 11:56:57 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 597k | -477k | -0.0035 | -3.71 | 1.76M |
From May 2019 to May 2024
TIDMPYC
RNS Number : 2352E
Physiomics PLC
05 May 2017
Physiomics Plc
("Physiomics" or "the Company")
Physiomics to Present at BioTrinity 2017
Oxford, UK, 5(th) May 2017: Physiomics is pleased to announce that it will attend BioTrinity 2017. BioTrinity is one of Europe's leading Biopartnering and Investment Conferences, to be held on 8-10 May at the Novotel London West.
In addition to participating in a number of partnering meetings, Physiomics will present an update on its technology at the conference on Tuesday 9(th) May. Dr Jim Millen, CEO, will speak at 2.30pm during the Early Stage Showcase 4 session.
Founded and produced by OBN, BioTrinity is now in its 11th year. BioTrinity continues to grow with more than 1000 senior executives and decision makers from emerging and established companies across the life sciences sector and investment firms are expected to attend.
John Harris, CEO of OBN, said: "We are delighted that Physiomics will be presenting at BioTrinity this year. BioTrinity is the perfect platform for life science companies to showcase their innovation and seek out their next deal. This year again we are thrilled to be hosting what we believe will be the great business development opportunity of 2017."
For further information on Physiomics please contact:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
WH Ireland Limited (NOMAD)
Katy Mitchell
+44 (0) 161 832 2174
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
For further information on OBN please contact:
OBN
Jane O'Driscoll, Head of Events
+(44) 1235 420 875
Email: Jane.odriscoll.co.uk
Citigate Dewe Rogerson
Sylvie Berrebi
Tel: +44 (0)20 7282 1052
Email: Sylvie.berrebi @citigatedr.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLLFISEDISIID
(END) Dow Jones Newswires
May 05, 2017 02:00 ET (06:00 GMT)
1 Year Physiomics Chart |
1 Month Physiomics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
